STAT+: Merck is a new year outlier with its diabetes drug

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Happy New Year, biotech friends! We’re back with news, including Merck’s decision to cut the price of its diabetes drug Januvia by 42% and Neumora’s readout on its  experimental depression drug. Also, is the best way to “save the FDA” to break it apart?

Merck is a new year outlier with its diabetes drug

From STAT’s Elaine Chen: The start of the new year is traditionally a time when many drugmakers raise the price of their treatments, and this year, companies did just that with at least 250 medicines. But Merck stood out by cutting the list price of its diabetes drug Januvia by 42%.

Continue to STAT+ to read the full story…